Amgen Combination Therapy Cuts Death Risk 58% in Lung Cancer Trial
Amgen’s Imdelltra, combined with AstraZeneca’s Imfinzi, reduced the risk of death by 58% versus Imfinzi alone in patients with extensive-stage small cell lung cancer, according to trial data presented at a medical meeting.